Sometimes facts lie. More specifically, they don't tell the whole truth. Implant Sciences' (IMSC.PK) third quarter and nine month results showed dramatic gains in revenues, 84 percent in Q3, 237 percent for the nine month period. On the face of it, exceptional.
However, the company also reported a net loss for the third quarter of $5.3 million compared to $3.9 the prior year, and a net loss of $21.8 million for the nine month period compared to a net loss of $10.3 million the prior nine months. On the face of it, depressing.
So what is it!? Does rapid top line growth indicate the company will shortly turn the corner to profitability? Or will bottom line hemorrhaging mean the company...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|